Wuhan Institute of Biological Products and Refine Technology Collaborate on Vaccines

by Richard Daverman, PhD

July 20, 2012 -- The Wuhan Institute of Biological Products (WIBF) formed a collaboration with Refine Technology, a US maker of biological manufacturing equipment. WIBF is a division of China National Biological Group, a Sinopharm subsidiary. WIPF and Refine will use Refine’s ATF™ System, a cell retention device, to improve the yield and reduce the cost of vaccine manufacturing. The collaboration will work on a specific novel vaccine, which was not identified. More details....

Back to news